ReviewCells2019
New Challenges of HIV-1 Infection: How HIV-1 Attacks and Resides in the Central Nervous System.
Review in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Pooled it
- Discovery of 4-Quinazolinone-Containing Phenylalanine Derivatives as Potent, Resistant-Tolerant HIV Capsid Inhibitors.MedComm · 2026Article
- Altered neurovascular coupling in patients with human immunodeficiency virus-associated asymptomatic neurocognitive impairment: a multimodal magnetic resonance imaging study.Quantitative imaging in medicine and surgery · 2026Article
- Metformin promotes PEN2 expression to attenuate microglia-mediated neurotoxicity induced by HIV-1 Tat.Journal of neurovirology · 2025Article
- Involvement of lncRNAs NEAT1 and ZBTB11-AS1 in Active and Persistent HIV-1 Infection in C20 Human Microglial Cell Line.International journal of molecular sciences · 2025Article
- Characteristics of cortical thickness in treated HIV-infected individuals with and without cognitive impairment.European journal of medical research · 2025Article
- Risk factors for cognitive decline in persons with HIV.Current opinion in infectious diseases · 2025Review
- Pathogenesis of HIV-associated depression: contributing factors and underlying mechanisms.Frontiers in psychiatry · 2025Review
- Functional alteration of divided attention in people living with HIV based on a task-fMRI study.Frontiers in neuroscience · 2025Article
- Editorial: Neurocognitive dysfunction in people living with HIV and the underlying brain mechanisms.Frontiers in neurology · 2025Article
- Infections in Moyamoya Phenomenon: Current Evidence and Future Horizons-Narrative Review.International journal of general medicine · 2025Review
- Sustained Delivery of Dolutegravir Sodium for Better Management of HIV/AIDSCurrent HIV research · 2025Article
- Importance of trace elements in the immunometabolic health of people living with HIV/AIDS: a literature review.Molecular biology reports · 2024Review
- HIV-Associated Neurocognitive Disorder: A Look into Cellular and Molecular Pathology.International journal of molecular sciences · 2024Review
- Molecular Role of HIV-1 Human Receptors (CCL5-CCR5 Axis) in neuroAIDS: A Systematic Review.Microorganisms · 2024Review
- Altered metabolism in right basal ganglia associated with asymptomatic neurocognitive impairment in HIV-infected individuals.Heliyon · 2024Article
- Application status and prospects of multimodal EEG-fMRI in HIV-associated neurocognitive disorders.Frontiers in neurology · 2024Review
- Bridging brain and blood: a prospective view on neuroimaging-exosome correlations in HIV-associated neurocognitive disorders.Frontiers in neurology · 2024Review
- Unveiling neuroimmunology profile of immunological non-responders in HIV: a multimodal MRI approach.Frontiers in immunology · 2024Article
- The Use of CBD and Its Synthetic Analog HU308 in HIV-1-Infected Myeloid Cells.Pharmaceuticals (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acquired immunodeficiency syndrome (AIDS) has become one of the most devastating pandemics in recorded history. The main causal agent of AIDS is the human immunodeficiency virus (HIV), which infects various cell types of the immune system that express the CD4 receptor on their surfaces. Today, combined antiretroviral therapy (cART) is the standard treatment for all people with HIV; although it has improved the quality of life of people living with HIV (PLWH), it cannot eliminate the latent reservoir of the virus. Therefore HIV/AIDS has turned from a fatal disease to a chronic disease requiring lifelong treatment. Despite significant viral load suppression, it has been observed that at least half of patients under cART present HIV-associated neurocognitive disorders (HAND), which have been related to HIV-1 infection and replication in the central nervous system (CNS). Several studies have focused on elucidating the mechanism by which HIV-1 can invade the CNS and how it can generate the effects seen in HAND. This review summarizes the research on HIV-1 and its interaction with the CNS with an emphasis on the generation of HAND, how the virus enters the CNS, the relationship between HIV-1 and cells of the CNS, and the effect of cART on these cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.